期刊
MOLECULES
卷 26, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/molecules26051488
关键词
cyclin-dependent kinase; cancer; resistance; small molecule inhibitors; PROTACs
资金
- MDPI
Inhibition of cyclin dependent kinases 4 and 6 has shown efficacy in treating aromatase inhibitor resistant metastatic breast cancer. Recent advancements have led to the development of new selective CDK4/6 inhibitors with enhanced selectivity and treatment efficacy, aiming to reduce adverse effects.
The inhibition of cyclin dependent kinases 4 and 6 plays a role in aromatase inhibitor resistant metastatic breast cancer. Three dual CDK4/6 inhibitors have been approved for the breast cancer treatment that, in combination with the endocrine therapy, dramatically improved the survival outcomes both in first and later line settings. The developments of the last five years in the search for new selective CDK4/6 inhibitors with increased selectivity, treatment efficacy, and reduced adverse effects are reviewed, considering the small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) approaches, mainly pointing at structure-activity relationships, selectivity against different kinases and antiproliferative activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据